Friday, October 7, 2022

Aussie health tech firm launches 3D body scanning technology for iPhones

0
Aussie health tech firm, mPort, is revolutionising the way we navigate our health and fitness journeys with the introduction of ‘Bodymapp’; the Ausssie-first accurate 3D body scanning feature available for iPhone users. This enables iPhone users to accurately capture their body measurements from the comfort of their own homes, using the smartphone’s depth sensors.

Cognizant partners with Organon to bolster their supply chain process

0
Cognizant has signed a multi-year agreement with Organon, a global women’s health firm, to help improve the company’s delivery of healthcare products and crucial medicinal supply chain management. Through the agreement, Cognizant will help scale Organon’s healthcare business by delivering full-stack industrial technology support for the company’s nemerous global pharmaceutical manufacturing sites in the UK, Netherlands, Belgium and Indonesia.

How preventative heart health curbs the risk to a heart attack tomorrow

0
Unfortunately, many of us today are far better at looking after our material possessions than we do for ourselves. Often we think that we are indestructible. We should really be focusing on good maintenance and prevention and shift from responding to problems to preventing problems - we would all agree that an ounce of prevention is worth a pound of cure.

New research identifies effective treatment against blood cancers

0
Researchers at QIMR Berghofer and Peter MacCallum Cancer Centre have discovered a new vital clue to improving immunotherapy to fight blood cancers such as leukaemia and myeloma. A new type of immunotherapy called T cell engaging bispecific therapy has shown great potential for treating blood cancers and is already being widely tested in clinical trials.

Hintsa Performance raises €5.1m to expand its holistic wellbeing solutions

0
Hintsa Performance, a high-performance coaching and wellbeing company, has raised €5.1 millions in new funding from notable investors, including ex-Unilever CEO Paul Polman, K5 Global, The Late Late Show host James Corden, and Charles Plowden, former joint senior partner of Baillie Gifford & Co, who will be the incoming Chair of the Board at Hintsa.

Acoustiic closes funding round, expands its team and facilities

0
Acoustiic, Inc., a healthcare firm at the forefront of next-generation therapeutic ultrasound systems, announced closing a funding round and expanding its team and facilities to develop non-invasive, early treatment of multiple diseases. The firm is creating an ultrasound tech platform for the treatment of a wide variety of potential clinical indications in a compact, modular, and versatile system to further improve patient outcomes and lowering costs.

Cardo Health teams up with Prosperia to bring digital healthcare to Mexico

0
Cardo Health is partnering with MIT Media Lab social impact spinoff, Prosperia, to bring digital healthcare to Mexico. Prosperia has developed an integrated artificial intelligence-based solution to massify early detection and treatment of diabetes and is now looking to expand its services, offering high quality digital healthcare to Mexico’s over 130 million inhabitants.

Cancer Council and Federal Gov’t push for the bowel screening test

0
Australia's bathroom habits are in the spotlight today as Cancer Council and the Australian Government encourage all Australians aged 50-74 to Get2it and participate in the National Bowel Cancer Screening Program (NBCSP) when they receive their free test kit in the mail. 

Mary Kay Inc. partners with Dr. Jack Gilbert to study skin’s Microbiome

0
Mary Kay Inc., a skincare research firm, has announced a partnership with Dr. Jack Gilbert, professor of pediatrics at the University of California San Diego School of Medicine and professor of microbial oceanography at UC San Diego Scripps Institution of Oceanography.

Boehringer Ingelheim, Evotec and bioMérieux launch a joint venture

0
Boehringer Ingelheim, a biopharmaceutical firm, the life science firm Evotec SE and bioMérieux, a vitro diagnostics firm, have formed a joint venture to create the next gen of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).